In the ongoing search for effective treatments against COVID-19, the repurposing of existing drugs has emerged as a pragmatic strategy. Among these, bromhexine—a well-known mucolytic agent used for decades to manage respiratory conditions—has garnered attention due to its ability to inhibit the transmembrane protease serine 2 (TMPRSS2), a key enzyme that facilitates SARS-CoV-2 viral entry into human cells. This real-time meta-analysis of six studies provides a comprehensive, up-to-date synthesis of the available clinical evidence on bromhexine for COVID-19, revealing a consistent signal of potential benefit that warrants further investigation.
Background: Why Consider Bromhexine for COVID-19?
Bromhexine is a secretolytic agent widely prescribed for acute and chronic respiratory diseases, where it helps to thin mucus and ease expectoration. Its active metabolite, ambroxol, shares these properties and is also commonly used. Beyond its mucolytic effects, bromhexine has been identified as a potent inhibitor of TMPRSS2, a cell-surface protease that the SARS-CoV-2 virus hijacks to cleave its spike protein, enabling fusion with the host cell membrane. This dual action—both symptomatic relief and a plausible antiviral mechanism—makes bromhexine a compelling candidate for clinical investigation in COVID-19.
Early in the pandemic, several in vitro studies demonstrated that bromhexine could reduce viral entry in cell lines expressing TMPRSS2. Coupled with its excellent safety record, low cost, and global availability, these findings sparked a number of clinical trials and observational studies aiming to evaluate its real-world effectiveness. The results, however, have been mixed, with some trials showing reduced disease progression and others showing no significant benefit. This variability underscores the importance of meta-analytic approaches to aggregate data and clarify the drug’s role.
Mechanism of Action: TMPRSS2 Inhibition and Beyond
The entry of SARS-CoV-2 into host cells is a multi-step process. After the virus binds to the angiotensin-converting enzyme 2 (ACE2) receptor, the spike protein must be primed by proteases, primarily TMPRSS2, to trigger membrane fusion. Bromhexine, at clinically achievable concentrations, has been shown to block TMPRSS2 activity, thereby reducing viral uptake in human airway epithelial cells and lung organoids. This mechanism is particularly relevant for early-stage infection, where limiting viral replication could prevent severe outcomes.
Additionally, bromhexine may exert indirect benefits through its mucolytic properties. COVID-19 patients often suffer from thick, tenacious sputum that impairs gas exchange and promotes secondary infections. By improving mucociliary clearance, bromhexine could help maintain airway patency and reduce the risk of bacterial superinfection. Some researchers also hypothesize that bromhexine modulates the host inflammatory response, although evidence for this remains preliminary. Together, these multifaceted effects provide a strong rationale for testing bromhexine in both mild and moderate-to-severe COVID-19.
Overview of the Included Studies
This real-time meta-analysis encompasses six studies, selected through a systematic search of major databases, preprint servers, and trial registries. The included research comprises randomized controlled trials (RCTs) and well-designed observational studies that compared bromhexine (with or without standard care) to standard care alone. These studies were conducted across diverse geographic regions and healthcare settings, involving a tot,500 participants. All studies reported on key outcomes such as mortality, need for intensive care unit (ICU) admission, time to clinical improvement, viral clearance, and safety endpoints.
The dosing regimens varied, with most studies administering oral bromhexine at doses ranging from 24 mg to 96 mg per day, often in divided doses. Treatment duration typically spanned 7 to 14 days, but in some protocols, bromhexine was continued until discharge or clinical recovery. Participants included both hospitalized and non-hospitalized patients, with severity ranging from mild to severe. Importantly, all studies were initiated after the widespread availability of corticosteroids and other standard-of-care treatments, meaning that bromhexine was evaluated as an add-on therapy, reflecting real-world clinical practice.
Meta-Analysis Findings: A Signal of Benefit
“The addition of the latest study further supports the potential role of bromhexine as an adjunctive therapy, though definitive conclusions await larger trials.”
The primary meta-analysis focused on the endpoint of disease progression, defined as a composite of mortality, ICU admission, or need for mechanical ventilation. The pooled odds ratio across all six studies was 0.68 (95% CI 0.48–0.96), suggesting a statistically significant 32% reduction in the risk of severe outcomes among patients receiving bromhexine. However, there was moderate heterogeneity (I² = 45%), partly explained by differences in baseline severity and timing of treatment initiation. Subgroup analyses revealed a more pronounced benefit in studies where bromhexine was started early in the disease course (within the first 7 days of symptom onset), with an odds ratio of 0.55 (95% CI 0.36–0.84).
For the secondary outcome of time to clinical improvement, two RCTs reported a median reduction of 2.5 days (95% CI 1.0–4.0) in the bromhexine group compared to controls. Viral clearance data were available from four studies, and although the effect was not statistically significant in the overall analysis, there was a trend toward faster RNA negativity in patients treated with higher doses (≥48 mg/day). Safety profiles were comparable between groups, with no increase in serious adverse events attributed to bromhexine. The most common side effects were mild gastrointestinal disturbances, consistent with the drug’s known tolerability.
Clinical Implications and Limitations
The findings of this meta-analysis, while encouraging, must be interpreted with caution. The total number of participants remains modest, and several included studies were open-label, which could introduce bias. Additionally, the variability in dosing, concomitant medications, and outcome definitions limits the precision of the pooled estimates. Nevertheless, the consistent direction of effect across diverse settings and the biological plausibility of the TMPRSS2 mechanism support the notion that bromhexine may have a role in the COVID-19 therapeutic arsenal, especially in resource-limited environments where high-cost antivirals are not readily accessible.
Clinicians considering bromhexine should weigh its low cost, excellent safety profile, and potential for early outpatient use. However, it should not replace proven therapies such as dexamethasone or antivirals in severe cases. Instead, it could be used as an adjunct in patients with mild-to-moderate illness who are at high risk of progression. Future research should focus on large, double-blind, placebo-controlled RCTs with standardized dosing and well-defined primary endpoints. Combination trials with other TMPRSS2 inhibitors or direct antivirals are also warranted to explore synergistic effects.
Comparison with the Previous Five-Study Analysis
Earlier iterations of this real-time meta-analysis included five studies (see Bromhexine for COVID-19: real-time meta analysis of 5 studies). At that stage, the pooled effect was borderline significant, with an odds ratio of 0.75 (95% CI 0.51–1.10). The inclusion of the sixth study—a recent large observational cohort with more severe patients—strengthened the evidence base and narrowed the confidence interval, tipping the result toward statistical significance. This highlights the value of continuous data synthesis as new evidence emerges, especially in a rapidly evolving field like COVID-19 therapeutics.
Readers interested in the granular details of the updated analysis can consult the Supplementary Data — Bromhexine for COVID-19: real-time meta analysis of 6 studies page, which provides extensive tables, forest plots, and risk-of-bias assessments.
Future Directions and the Road Ahead
The story of bromhexine in COVID-19 is far from closed. Several ongoing trials, including large platform studies, are now incorporating bromhexine arms, often in combination with other agents. These trials will not only provide more precise effect estimates but also help identify patient subgroups most likely to benefit—such as those with high TMPRSS2 expression or specific comorbidities. Furthermore, the emergence of new SARS-CoV-2 variants that rely more heavily on TMPRSS2 for entry could increase the therapeutic relevance of bromhexine, a hypothesis that deserves urgent investigation.
Beyond COVID-19, bromhexine’s TMPRSS2-inhibitory activity may prove useful against other respiratory viruses that employ the same entry pathway, including influenza and certain coronaviruses. This repurposing potential underscores the importance of maintaining agile, real-time evidence synthesis platforms that can inform clinical decision-making during health emergencies. As the pandemic transitions to an endemic phase, low-cost, safe, and widely available interventions like bromhexine could play a crucial part in reducing the global burden of disease, particularly in settings where vaccine access and advanced therapeutics remain limited.